Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
Wolf
J A
JA
University of Texas Health Science Center, Houston.
Grimm
E A
EA
D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000502:physiology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology; D009369:Neoplasms / Q000628:therapy*
D007376:Interleukin-2